Device Trial Radar · NCT03511638
Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)
Last checked: Nov 20, 2026Latest source record: Oct 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
372
Actual
Start
May 9, 2018
Primary completion
Apr 1, 2019
Study completion Apr 1, 2019
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 30, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD
Conditions
- Cataract
Interventions
Bausch & Lomb DVisc40Device
Ophthalmic viscosurgical device
Alcon VISCOAT®Device
Ophthalmic viscosurgical device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Mean Epithelial Cell Density (ECD)Time frame: Day 90
- Percentage of Participants With Postoperative Intraocular Pressure of at Least 30 mm HgTime frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Valeant Site 01
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.